Brian Daniel Webster - 17 Feb 2026 Form 4 Insider Report for KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS)

Signature
/s/ Brian Daniel Webster
Issuer symbol
KMTS
Transactions as of
17 Feb 2026
Net transactions value
-$384,020
Form type
4
Filing time
19 Feb 2026, 16:35:14 UTC
Previous filing
20 Jan 2026

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Webster Brian Daniel President and Chief Executive Officer, Director 3933 LAKE WASHINGTON BLVD NE, SUITE 200, KIRKLAND /s/ Brian Daniel Webster 19 Feb 2026 0001877188

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KMTS Common Shares Sale $295,456 -11,635 -2.9% $25.39 383,151 17 Feb 2026 Direct F1, F2
transaction KMTS Common Shares Sale $86,036 -3,272 -0.85% $26.29 379,879 17 Feb 2026 Direct F1, F3
transaction KMTS Common Shares Sale $2,528 -93 -0.02% $27.18 379,786 17 Feb 2026 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The reported transaction occurred pursuant to a Rule 10b5-1 trading plan adopted on September 29, 2025.
F2 The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $25.0150 to $26.0100. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.
F3 The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $26.0200 to $26.9998. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.
F4 The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $27.0771 to $27.1800. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.

Remarks:

President and Chief Executive Officer